Industry Overview - The Chinese clinical CRO industry is entering a recovery and stable growth phase, transitioning from an offshore outsourcing model to a global contributor of innovative assets over the past decade [2][13] - The industry experienced a growth phase from 2017-2019 and a rapid development period from 2020-2022, with a forecasted compound annual growth rate (CAGR) of over 12% from 2025 to 2028, expecting to exceed 75 billion RMB by 2028 [2][13] - As of December 2025, the average number of clinical trial projects undertaken by each clinical CRO in China increased by 20.6% year-on-year, reaching 42.9 projects, narrowing the gap with the U.S. [5][16] Investment Trends - The investment from multinational pharmaceutical companies in China's clinical trials remains stable, with 25%-30% of Phase III innovative drug trials initiated by these companies over the past eight years [6][17] - Local pharmaceutical companies are also actively investing in innovative drug clinical research, contributing 15%-20% of Phase III trials in China during the same period [6][17] - The financing channels for Chinese innovative drugs have diversified, with a significant increase in licensing and mergers and acquisitions (M&A) transactions, totaling 178 deals in 2024-2025 [9][20] Company Highlights - Tigermed has ranked first in market share in China's clinical CRO sector for several years, with a compound annual growth rate of 14.8% in new orders from 2019 to 2024, surpassing the market's growth rate of 12.5% [11][23] - The average price of domestic clinical trial services is stabilizing after fluctuations in 2022-2023, indicating strong business continuity and resilience [11][23] - In 2025, Tigermed aims for sustainable development, achieving an AAA rating in MSCI ESG, and enhancing its service capabilities through the acquisition of CRO company Micron [11][23] - The company is investing in AI applications and platforms, launching an AI medical translation platform and an AI medical writing platform in 2025 [11][23]

Core Viewpoint - On January 15, Tiger Med experienced a slight decline of 0.38% with a trading volume of 700 million yuan, indicating a low level of financing and margin trading activity [1][2]. Financing Summary - On January 15, Tiger Med had a financing buy amount of 39.99 million yuan and a financing repayment of 40.44 million yuan, resulting in a net financing outflow of 446,300 yuan. The total financing and margin trading balance reached 675 million yuan [1]. - The current financing balance is 673 million yuan, which accounts for 1.45% of the circulating market value, indicating a low level compared to the past year [1]. Margin Trading Summary - On January 15, Tiger Med repaid 100 shares in margin trading and sold 1,300 shares, with a selling amount of 81,600 yuan based on the closing price. The margin trading balance is 1.59 million yuan, which is also low compared to the past year [1]. Company Overview - Tiger Med, established on December 15, 2004, and listed on August 17, 2012, is located in Hangzhou, Zhejiang Province. The company specializes in providing professional clinical research services for domestic and international pharmaceutical and health-related products [2]. - The main business revenue composition includes clinical trial-related services and laboratory services (52.60%), clinical trial technical services (45.21%), and other services (2.19%) [2]. Financial Performance - For the period from January to September 2025, Tiger Med reported a revenue of 5.026 billion yuan, a year-on-year decrease of 0.82%. However, the net profit attributable to the parent company was 1.020 billion yuan, reflecting a year-on-year increase of 25.45% [2]. Dividend Information - Since its A-share listing, Tiger Med has distributed a total of 2.458 billion yuan in dividends, with 1.154 billion yuan distributed over the past three years [3]. Shareholder Information - As of September 30, 2025, Tiger Med had 48,400 shareholders, a decrease of 6.01% from the previous period. The average circulating shares per person remained at 0 shares [2][3]. - The second-largest circulating shareholder is Hong Kong Central Clearing Limited, holding 48.3625 million shares, an increase of 25.0969 million shares from the previous period [3].

Group 1 - Citi has initiated a 90-day upward catalyst observation for Tigermed (03347.HK) with a target price of HKD 73 and a "Buy" rating [1] - Tigermed will participate in a healthcare conference in the U.S. and is expected to share optimistic industry trends and 2026 outlook due to strong performance in China's innovative drug research and a recovering funding environment [1] - The company is set to release its 2025 performance in March and provide guidance for 2026, with an anticipated 44% growth in operating profit by 2026 [1] Group 2 - As of January 14, 2026, Tigermed's stock closed at HKD 53.0, down 0.93%, with a trading volume of 3.6978 million shares and a turnover of HKD 199 million [1] - Tigermed's market capitalization is HKD 6.587 billion, ranking 12th in the healthcare services sector [1] - Key performance indicators for Tigermed compared to industry averages are as follows: ROE at 1.45% (industry average 1.62%), market capitalization at HKD 6.587 billion (industry average HKD 8.771 billion), revenue at HKD 6.495 billion (industry average HKD 3.901 billion), net profit margin at 11.16% (industry average -963.25%), gross margin at 30.09% (industry average 41.13%), and debt ratio at 15.93% (industry average 74.33%) [1]

Group 1 - The core viewpoint of the report is that Citigroup has initiated a 90-day upward catalyst observation for Tigermed (300347)(03347), setting a target price of HKD 73 and a "Buy" rating [1] - Tigermed is set to participate in a healthcare conference in the United States where it will deliver a presentation, which is expected to highlight optimistic industry trends and prospects up to 2026 due to strong performance in China's innovative drug research and a recovering funding environment [1] - The company is scheduled to release its 2025 performance results in March and provide guidance for 2026, with expectations of a cautious tone from management, but potential for upward revisions in the 2026 guidance, projecting a 44% increase in operating profit for that year [1]

Group 1 - Citi has initiated a 90-day upward catalyst observation for Tiger Medical (03347) with a target price of HKD 73 and a "Buy" rating [1] - Tiger Medical will participate in a healthcare conference in the US and deliver a presentation [1] - Due to the strong performance of China's innovative drug research and a recovering funding environment, it is expected that management will share optimistic industry trends and outlook for 2026 [1] Group 2 - The company is set to release its 2025 performance results in March and provide guidance for 2026 [1] - Management's tone is perceived as cautious, but there is potential for upward guidance for 2026, with an expected operating profit growth of 44% [1]

Group 1 - Citi has initiated a 90-day upward catalyst observation for Tiger Medical, noting the company's participation in a healthcare conference in the U.S. where it will deliver a speech [1] - Due to the strong performance of China's innovative drug research and a recovering funding environment, Citi expects management to share optimistic industry trends and outlooks for 2026 [1] - The company is set to release its 2025 earnings in March and provide guidance for 2026, with management's tone leaning towards caution, but with potential upside in the 2026 guidance, anticipating a 44% growth in operating profit [1] - Citi has set a target price of HKD 73 and a "Buy" rating for the company [1]

Core Viewpoint - Tiger Med's stock price has shown significant growth in recent months, with a year-to-date increase of 13.28% and a 30.31% rise over the past 20 trading days [1]. Group 1: Stock Performance - As of January 14, Tiger Med's stock price reached 64.23 CNY per share, with a trading volume of 1.49 billion CNY and a market capitalization of 55.304 billion CNY [1]. - The stock experienced a 2.11% increase during the trading session on January 14 [1]. - The stock has seen a 6.52% increase over the last five trading days and an 18.77% increase over the last 60 days [1]. Group 2: Financial Performance - For the period from January to September 2025, Tiger Med reported a revenue of 5.026 billion CNY, a year-on-year decrease of 0.82%, while the net profit attributable to shareholders increased by 25.45% to 1.020 billion CNY [2]. Group 3: Shareholder Information - As of September 30, 2025, the number of shareholders for Tiger Med was 48,400, a decrease of 6.01% from the previous period [2]. - The company has distributed a total of 2.458 billion CNY in dividends since its A-share listing, with 1.154 billion CNY distributed over the last three years [3]. - The second-largest shareholder, Hong Kong Central Clearing Limited, increased its holdings by 25.097 million shares to 48.3625 million shares [3].

里昂发布研报称，2026年将是中国生物科技行业的转折点，泰格医药(03347)仍是投资中国创新药的首 选，基于最新的行业及公司预测，该行将泰格医药目标价由52.1港元上调至57.2港元，并重申"跑赢大 市"评级。 里昂相信，2026年该板块将呈现两大发展方向，包括1)中国临床CRO行业在整合后迎来转折点，更合理 的定价将推动行业边际利润修复; 2)H股创新药板块走强，将支撑泰格医药投资组合项目的退出表现。 里昂将泰格医药的估值基准滚动至2027年，预计泰格医药2026至2027年的盈利增长可达7%至12%，并 认为投资收益将更可预测且可持续。 ...

里昂相信，2026年该板块将呈现两大发展方向，包括1)中国临床CRO行业在整合后迎来转折点，更合理 的定价将推动行业边际利润修复;2)H股创新药板块走强，将支撑泰格医药投资组合项目的退出表现。里 昂将泰格医药的估值基准滚动至2027年，预计泰格医药2026至2027年的盈利增长可达7%至12%，并认 为投资收益将更可预测且可持续。 里昂发布研报称，2026年将是中国生物科技行业的转折点，泰格医药（300347）(03347)仍是投资中国 创新药的首选，基于最新的行业及公司预测，该行将泰格医药目标价由52.1港元上调至57.2港元，并重 申"跑赢大市"评级。 ...

里昂发表报告指出，2026年将是中国生物科技行业的转折点，泰格医药仍是投资中国创新药的首选。该 行将其目标价由52.1港元上调至57.2港元，并重申"跑赢大市"评级。里昂相信，2026年该板块将呈现两 大发展方向，包括1)中国临床CRO行业在整合后迎来转折点，更合理的定价将推动行业边际利润修复； 2)H股创新药板块走强，将支撑泰格医药投资组合项目的退出表现。 ...